LifeScience BioSimilar
Cytiva Introduces MabSelect SuRe 70 & PrismA X to Boost Cost-Efficient mAb Purification
MabSelect SuRe 70 and MabSelect PrismA X resins to set new standards in affordability and productivity Cytiva's expanded resin portfolio wil...
April 04, 2025 | News
Celltrion’s Biosimilar STEQEYMA® Added to Costco Member Prescription Program to Expand Access and Affordability
STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 Celltrion'...
March 28, 2025 | News
Celltrion Launches STEQEYMA®, a Biosimilar to STELARA®, in the U.S. at an 85% Lower WAC List Price
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as the reference produc...
March 13, 2025 | News
Celltrion’s OMLYCLO® Becomes First FDA-Approved Interchangeable Biosimilar to XOLAIR®
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for intercha...
March 10, 2025 | News
Celltrion Secures FDA Approval for STOBOCLO® and OSENVELT® as Biosimilars to PROLIA® and XGEVA®
STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA®&nbs...
March 05, 2025 | News
SmithRx Expands Connect 360 Autoimmune Program Adding Stelara Biosimilars and Partnering with Costco Specialty Pharmacy
SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), announced a major expansion to its Connect 360 Autoimmune Program, ...
March 03, 2025 | News
South Korea’s Celltrion Secures EU Approval for Three Biosimilar Products, Expanding Its Portfolio to 11 by 2025
Celltrion gains simultaneous regulatory approval of two monoclonal antibody biosimilars across three treatments – Eydenzelt® (aflibe...
February 19, 2025 | News
Celltrion Secures FDA Approval for AVTOZMA® Biosimilar to ACTEMRA® in IV and SC Formulations
AVTOZMA® will be available as both intravenous (IV) and subcutaneous (SC) formulations with the same formulations and dosages as the reference p...
January 31, 2025 | News
Taiwan’s Taikang Biotech Joins Forces with Mitsubishi Gas Chemical and Taiwan Sugar Alliance to Propel SPD8 Biosimilar Globally
Taikang Biotech (6589), Mitsubishi Gas Chemical Co., Ltd. (MGC), and the Taiwan Sugar Association (4168) have entered into a strategic tripartite agreement...
December 26, 2024 | News
CHMP Endorses Celltrion’s Biosimilars Eydenzelt Stoboclo Osenvelt and Avtozma for Expanded Access to Biologic Treatments
The Committee for Medicinal Products for Human Use (CHMP) adopts positive opinions for Celltrion’s three biosimilar candidates – Eydenz...
December 16, 2024 | News
GCCL Launches R&D Division to Bolster Biosimilar and Clinical Trial Analysis Services
Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis Including blockb...
July 17, 2024 | News
Biocon Biologics Teams Up with Sandoz Australia for Biosimilar Trastuzumab and Bevacizumab
Under the agreement, Sandoz will distribute the Biocon Biologics' brands, OGIVRI® (bTrastuzumab) and ABEVMY® (bBevacizumab), and facilita...
February 09, 2024 | News
Mabxience and Abbott Forge Strategic Deal to Expand Biosimilars Access in Emerging Markets
Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia and Middle East and Africa mAbxience Holdi...
September 21, 2023 | News
Celltrion Celebrates a Decade of Biosimilar Innovation in Europe
Marking 10 years since the European Medicines Agency (EMA) approved the world’s first monoclonal antibody biosimilar infliximab, for all indication...
September 11, 2023 | News
Most Read
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
